Afrezza is the first approved inhalable insulin in Brazil, indicated to control high sugar levels in adults with diabetes mellitus.This insulin may replace rapid injectable insulins, which are commonly used in meals but are not suitable for long-acting insulin replacement, and should be used in combination with long-acting insulin in patients with type 1 diabetes mellitus.
This fast-acting inhaled insulin is now available in Brazil.
This medicine should be given at the beginning of the meal, through the inhaler, as directed by your doctor.
Afrezza insulin dissolves rapidly after inhalation into the lungs and immediately reaches the bloodstream.Maximum levels are reached between 12 and 15 minutes after administration of the drug and decrease by approximately 3 hours.
Afrezza should not be used by people with chronic lung diseases, such as asthma or chronic obstructive pulmonary disease, people who are hypersensitive to the components of the formula or who have already reacted to other insulins, should not be used to treat diabetic ketoacidosis, smokers and children under 18 years of age.Years.
In addition, your doctor should be informed if the person has a history of lung cancer, uses inhaled medications, has liver or kidney problems, and is pregnant or breastfeeding.
Some of the side effects that may occur during treatment with Afrezza are hypoglycemia, decreased lung function, lung cancer, diabetic ketoacidosis, allergic reactions, decreased blood potassium and heart failure.